Cyproheptadine (trade names include Periactin, Cipla-Actin, Ciplactin, Peritol, Practin, Pronicy, Viternum) is a first-generation antihistamine medication from antihistamines for systemic use pharmacological group. This medicine is prescribed for the therapy of hay fever, allergic rhinitis, other allergic reactions; as a preventive treatment against migraine, cluster headaches. It is also used off-label in the treatment of Cushing's syndrome, cyclical vomiting syndrome in infants, to improve akathisia in people on antipsychotic medications, to treat various dermatological conditions, including pruritus, urticaria, psychogenic itch, drug-induced hyperhidrosis (excessive sweating); prevention of blister formation for some people with epidermolysis bullosa simplex; to increase appetite and weight gain in people with anorexia, anorexia nervosa, cystic fibrosis, in children who are wasting or with failure to thrive; in the management of moderate to severe cases of serotonin syndrome, SSRI induced sexual dysfunction.
Cyproheptadine is also indicated in veterinary for cats as an appetite stimulant and as an adjunct in the treatment of asthma; as a second line treatment for pituitary pars intermedia dysfunction in horses.
It works as very potent antihistamine or inverse agonist of the H1 receptor.
How and where to order Periactin (Cyproheptadine) 4 mg tablets online on FLCPR:
|Prices:||from $0.39 per pill
|Discount:||10% coupon: DFHDCC
|Forms:||Cyproheptadine Hydrochloride 4 mg tablets
|Type:||Cyproheptadine brand, Periactin generic
|Payment:||Visa, MasterCard, AmEx, eCheck (ACH), Bitcoin
|Delivery:||Standard airmail and trackable courier services
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Pharmacological and medical categories:
Anti allergic drugs
Histamine H1-receptor antagonists
Serotonin receptor antagonists
Veterinary medications, pet meds
Weight gain pills
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AX - Other antihistamines for systemic use
R06AX02 - Cyproheptadine
Cushing's syndrome - E24
Cystic fibrosis - E84
Eating disorders - F50
Anorexia nervosa, unspecified - F50.00
Other extrapyramidal and movement disorders - G25
Drug induced akathisia - G25.71
Migraine - G43
Other headache syndromes - G44
Vasomotor and allergic rhinitis - J30
Allergic rhinitis due to pollen - J30.1
Pruritus - L29
Pruritus scroti - L29.1
Eccrine sweat disorders - L74
Primary focal hyperhidrosis, axilla - L74.510
Other disorders of the skin and subcutaneous tissue - L80-L99
Male erectile dysfunction - N52
Drug-induced erectile dysfunction - N52.2
Epidermolysis bullosa - Q81
Epidermolysis bullosa simplex - Q81.0
Nausea and vomiting - R11
Lack of expected normal physiological development in childhood and adults - R62
Adult failure to thrive - R62.7
Symptoms and signs concerning food and fluid intake - R63
Anorexia - R63.0
Superficial injury of knee and lower leg - S80
Blister (nonthermal), right lower leg, initial encounter - S80.821A
Poisoning by, adverse effect of and underdosing of psychotropic drugs, not elsewhere classified - T43
Indications and usage:
Perennial and seasonal allergic rhinitis
Allergic conjunctivitis due to inhalant allergens and foods
Mild, uncomplicated allergic skin manifestations of urticaria and angioedema
Amelioration of allergic reactions to blood or plasma
In migraine and vascular types of headache
As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
Dosage and administration:
Dosage of Periactin (Cyproheptadine) 4 mg tablets should be individualized according to the needs and the response of the patient.
Age 2 to 6 years. The total daily dosage for pediatric patients may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day or 8 mg per 2square meter of body surface (8 mg/m2). The usual dose is 2 mg (1/2 tablet) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 12 mg a day.
Age 7 to 14 years. The usual dose is 4 mg (1 tablet) two or three times a day adjusted as necessary to the size and response of the patient. The dose is not to exceed 16 mg a day.
The total daily dose for adults should not exceed 0.5 mg/kg/day. The therapeutic range is 4 to 20 mg a day, with the majority of patients requiring 12 to 16 mg a day. An occasional patient may require as much as 32 mg a day for adequate relief. It is suggested that dosage be initiated with 4 mg (1 tablet) three times a day and adjusted according to the size and response of the patient.
Dosage forms and strengths:
Periactin (Cyproheptadine Hydrochloride) 4 mg oral tablets.
Cyproheptadine and other antihistamines overdosage reactions may vary from central nervous system depression to stimulation especially in pediatric patients. Also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur.
If vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac.
If patient is unable to vomit, perform gastric lavage followed by activated charcoal. Isotonic or 1/2 isotonic saline is the lavage of choice. Precautions against aspiration must be taken especially in infants and children.
When life threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response, and recurrence after response.
Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid dilution of bowel content.
Stimulants should not be used.
Vasopressors may be used to treat hypotension.
The oral LD50 of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.
Cyproheptadine (Periactin) should not be used for therapy of an acute asthmatic attack.
Newborn or premature infants
This drug should not be used in newborn or premature infants. Use in infants has been associated with apnea, cyanosis, and respiratory difficulty.
Because of the higher risk of antihistamines for infants generally, and for newborn and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.
Hypersensitivity to cyproheptadine and other drugs of similar chemical structure
Monoamine oxidase inhibitor therapy
Stenosing peptic ulcer
Symptomatic prostatic hypertrophy
Bladder neck obstruction
Elderly, debilitated patients
Overdosage of cyproheptadine and other antihistamines, particularly in infants and young children, may produce hallucinations, central nervous system depression, convulsions, respiratory and cardiac arrest, and death.
Antihistamines may diminish mental alertness; conversely, particularly, in the young child, they may occasionally produce excitation.
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
Activities requiring mental alertness
Patients taken cyproheptadine should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery. Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.
Periactin (Cyproheptadine Hydrochloride) has an atropine-like action and, therefore, should be used with caution in patients with:
History of bronchial asthma
Increased intraocular pressure
Information for patients:
Antihistamines, including cyproheptadine may diminish mental alertness; conversely, particularly, in the young child, they may occasionally produce excitation. Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.
MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
Side effects, adverse reactions:
The side effects of cyproheptadine that appear frequently are drowsiness and somnolence. Many patients who complain initially of drowsiness may no longer do so after the first three or four days of continuous administration.
Adverse reactions which have been reported with the use of antihistamines:
Central nervous system: sedation, sleepiness (often transient), dizziness, disturbed co-ordination, confusion, restlessness, excitation, nervousness, tremor, irritability, aggressive behaviour, insomnia, paraesthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness
Integumentary: allergic manifestation of rash and oedema, excessive perspiration, urticaria, photosensitivity
Special senses: acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus
Cardiovascular: hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock
Haematological: haemolytic anaemia, leucopoenia, agranulocytosis, thrombocytopoenia
Digestive system: cholestasis, hepatic failure, hepatitis, hepatic function abnormality, dryness of mouth, epigastric distress, anorexia, nausea, vomiting, diarrhoea, constipation, jaundice
Genitourinary: frequency of micturition, difficult micturition, urinary retention, early menses
Respiratory: dryness of nose and throat, thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness, epistaxis
Miscellaneous: fatigue, chills, headache, increased appetite/weight gain
Use in specific populations:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from cyproheptadine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients below the age of two have not been established.
Clinical studies of Periactin (Cyproheptadine HCl) tablets 4 mg did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Use in pregnancy:
Reproduction studies have been performed in rabbits, mice, and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. No teratogenic effects were observed in any of the newborns. Nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed.
A - Australia
B - United States (No evidence of risk in humans)
Salts and other forms:
Cyproheptadine Hydrochloride Anhydrous
Cyproheptadine Hydrochloride Hydrate
Cyproheptadine Hydrochloride Monohydrate
Cyproheptadine Hydrochloride Sesquihydrate
Cyproheptadine Pyridoxal Phosphate
Synonyms, international and chemical names:
Chlorhydrate de Cyproheptadine
Brands, generics, trade names:
Cipla-Actin - Cipla
Ciplactin - Cipla, LBS Laboratory
Periactin - Merck, Avantgarde, B L Hua, Johnson & Johnson, M & H Manufacturing, Sigma-Tau Pharmaceuticals
Periactine - Merck, Teofarma
Peritol - Egis, Medphano Arzneimittel, Themis Medicare
PMS-Cyproheptadine - Pharmascience
Practin - Wockhardt
Pronicy - Kalbe Farma
Viternum - Labomed Instituto Farmaceutico, Juste Quimico-Farmaceutica, OM Pharma, Senosiain Laboratorios
APIs used in medicine in combinations with cyproheptadine::
Here is a list of popular medications containing cyproheptadine as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Tablets; Oral; Cyproheptadine Hydrochloride 4 mg
||Syrup; Oral; Cyproheptadine Hydrochloride 2 mg / 5 mlTablets; Oral; Cyproheptadine Hydrochloride 4 mg
||MerckAvantgardeB L HuaJohnson & JohnsonM & H ManufacturingSigma-Tau Pharmaceuticals
||Drops; Oral; Cyproheptadine Hydrochloride 1.5 mg / mlLiquid; Oral; Cyproheptadine Hydrochloride 1.5 mg / mlSyrup; Oral; Cyproheptadine Hydrochloride 2 mg / 5 mlTablets; Oral; Cyproheptadine Hydrochloride 4 mg
||EgisMedphano ArzneimittelThemis Medicare
Cyproheptadine main article on Wikipedia: https://en.wikipedia.org/wiki/Cyproheptadine
Cyproheptadine compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/cyproheptadine
Cyproheptadine Hydrochloride compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Cyproheptadine-hydrochloride
Cyproheptadine on DrugBank: https://go.drugbank.com/drugs/DB00434
Cyproheptadine Hydrochloride on DrugBank: https://go.drugbank.com/salts/DBSALT000625
Cyproheptadine FAQ on MedlinePlus (revised 02/15/2018): https://medlineplus.gov/druginfo/meds/a682541.html
Cyproheptadine Hydrochloride tablets drug label info on DailyMed (revised May 21, 2020): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Cyproheptadine containing drugs on Drugs-About.com: https://drugs-about.com/ing/cyproheptadine.html
Cyproheptadine for sale on Pharma Doctor: https://pharma-doctor.com/cyproheptadine.html
Cyproheptadine international drug names on Drugs.com: https://www.drugs.com/international/cyproheptadine.html
Teva Cyproheptadine Hydrochloride tablets USP 4 mg for oral use official prescribing information from the U.S. FDA: https://www.accessdata.fda.gov/drugsatfda_docs/label...
Periactin (Cyproheptadine Hydrochloride) 4 mg tablets product information from GP2U TeleHealth (revised 17 November 2011): https://gp2u.com.au/static/pdf/P/PERIACTIN-PI.pdf
Periactin (Cyproheptadine Hydrochloride Sesquihydrate) 4 mg tablets consumer medicine information from NPS MedicineWise (revised November 2020): https://www.nps.org.au/medicine-finder/periactin-tablets
Periactin (Cyproheptadine Hydrochloride) 4 mg tablets package information leaflet from Medicines.org.au (revised October 2007): https://apps.medicines.org.au/files/mkcperia.pdf
Revised: February 2021
Home | Research | About Us | Students | Board Members | Online Resources | Donors | Eszopiclone | Cyproheptadine | Selegiline | Research Grant | Awards | Contact Us
Copyright © 2007 - 2021 Foundation for Life Care Planning Research (FLCPR). All rights reserved.